Cargando…

Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden

Influenza illness is caused by influenza A and influenza B strains. Although influenza A viruses are perceived to carry greater risk because they account for the majority of influenza cases in most seasons and have been responsible for influenza pandemics, influenza B viruses also impose a substanti...

Descripción completa

Detalles Bibliográficos
Autores principales: Tisa, V., Barberis, I., Faccio, V., Paganino, C., Trucchi, C., Martini, M., Ansaldi, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore SRL 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910440/
https://www.ncbi.nlm.nih.gov/pubmed/27346937
_version_ 1782438012970336256
author Tisa, V.
Barberis, I.
Faccio, V.
Paganino, C.
Trucchi, C.
Martini, M.
Ansaldi, F.
author_facet Tisa, V.
Barberis, I.
Faccio, V.
Paganino, C.
Trucchi, C.
Martini, M.
Ansaldi, F.
author_sort Tisa, V.
collection PubMed
description Influenza illness is caused by influenza A and influenza B strains. Although influenza A viruses are perceived to carry greater risk because they account for the majority of influenza cases in most seasons and have been responsible for influenza pandemics, influenza B viruses also impose a substantial public health burden, particularly among children and at-risk subjects. Furthermore, since the 2001-2002 influenza season, both influenza B lineages, B/Victoria-like viruses and B/Yamagata-like viruses have co-circulated in Europe. The conventional trivalent influenza vaccines have shown a limited ability to induce effective protection when major or minor mismatches between the influenza B vaccine component and circulating strains occur. For this reason, the inclusion of a second B strain in influenza vaccines may help to overcome the well-known difficulties of predicting the circulating B lineage and choosing the influenza B vaccine component. Two quadrivalent influenza vaccines, a live-attenuated quadrivalent influenza vaccine (Q/LAIV) and a split inactivated quadrivalent influenza vaccine (I/QIV), were first licensed in the US in 2012. Since their introduction, models simulating the inclusion of QIV in influenza immunization programs have demonstrated the substantial health benefits, in terms of reducing the number of influenza cases, their complications and mortality. In the near future, evaluations from simulation models should be confirmed by effectiveness studies in the field, and more costeffectiveness analyses should be conducted in order to verify the expected benefits.
format Online
Article
Text
id pubmed-4910440
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Pacini Editore SRL
record_format MEDLINE/PubMed
spelling pubmed-49104402016-06-24 Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden Tisa, V. Barberis, I. Faccio, V. Paganino, C. Trucchi, C. Martini, M. Ansaldi, F. J Prev Med Hyg Research Article Influenza illness is caused by influenza A and influenza B strains. Although influenza A viruses are perceived to carry greater risk because they account for the majority of influenza cases in most seasons and have been responsible for influenza pandemics, influenza B viruses also impose a substantial public health burden, particularly among children and at-risk subjects. Furthermore, since the 2001-2002 influenza season, both influenza B lineages, B/Victoria-like viruses and B/Yamagata-like viruses have co-circulated in Europe. The conventional trivalent influenza vaccines have shown a limited ability to induce effective protection when major or minor mismatches between the influenza B vaccine component and circulating strains occur. For this reason, the inclusion of a second B strain in influenza vaccines may help to overcome the well-known difficulties of predicting the circulating B lineage and choosing the influenza B vaccine component. Two quadrivalent influenza vaccines, a live-attenuated quadrivalent influenza vaccine (Q/LAIV) and a split inactivated quadrivalent influenza vaccine (I/QIV), were first licensed in the US in 2012. Since their introduction, models simulating the inclusion of QIV in influenza immunization programs have demonstrated the substantial health benefits, in terms of reducing the number of influenza cases, their complications and mortality. In the near future, evaluations from simulation models should be confirmed by effectiveness studies in the field, and more costeffectiveness analyses should be conducted in order to verify the expected benefits. Pacini Editore SRL 2016-03 /pmc/articles/PMC4910440/ /pubmed/27346937 Text en © Copyright by Pacini Editore SRL, Pisa, Italy http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Research Article
Tisa, V.
Barberis, I.
Faccio, V.
Paganino, C.
Trucchi, C.
Martini, M.
Ansaldi, F.
Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
title Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
title_full Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
title_fullStr Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
title_full_unstemmed Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
title_short Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
title_sort quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910440/
https://www.ncbi.nlm.nih.gov/pubmed/27346937
work_keys_str_mv AT tisav quadrivalentinfluenzavaccineanewopportunitytoreducetheinfluenzaburden
AT barberisi quadrivalentinfluenzavaccineanewopportunitytoreducetheinfluenzaburden
AT facciov quadrivalentinfluenzavaccineanewopportunitytoreducetheinfluenzaburden
AT paganinoc quadrivalentinfluenzavaccineanewopportunitytoreducetheinfluenzaburden
AT trucchic quadrivalentinfluenzavaccineanewopportunitytoreducetheinfluenzaburden
AT martinim quadrivalentinfluenzavaccineanewopportunitytoreducetheinfluenzaburden
AT ansaldif quadrivalentinfluenzavaccineanewopportunitytoreducetheinfluenzaburden